20 results about "Flagellin" patented technology

Provided herein are recombinant microorganisms that express a subject polypeptide. Microorganisms can comprise an expression construct comprising a flagellin promoter operatively linked with a heterologous nucleotide sequence encoding the subject polypeptide. The flagellin promoter sequence can comprise a genetic modification that reduces CsrA inhibition of translation. Microorganisms also can comprise a genetic modification that reduces FlgM inhibition of SigD initiation of transcription. The target polypeptide can be an aldehyde dehydrogenase. Such microorganisms are useful in the treatment of alcohol hangover.

The invention relates to lipid nanoparticles containing an adjuvant for mucosal administration and a preparation method of the lipid nanoparticles. The lipid nanoparticles comprise total lipid, an adjuvant and an active ingredient, wherein the total lipid is composed of cationic lipid C12-200, non-cationic phospholipid, cholesterol and a derivative thereof, and pegylated lipid; wherein the adjuvant is selected from at least one of AS03, MF59, monophosphoryl lipid A, miniaturized monophosphoryl lipid A, ophiopogonin D, saponin QS21, QS7, QS17, QS18, CpG oligonucleotide, 2 '3'-ring GMP-AMP, 3 '3'-ring GMP-AMP, alpha GC, Trehalose-6, 6-dibehenate, cholera toxin B subunit and flagellin.

Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of Lachnospiraceae flagellin peptides, which can be selected from a hinge region of Lachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.

The invention belongs to the field of aquatic bacteria detection, and relates to a fluorescent array sensor as well as a preparation method and application thereof. The fluorescent array sensor comprises a plurality of DNA aptamers, the DNA aptamers respectively target lipopolysaccharide, peptidoglycan and flagellin, the DNA aptamers of the target lipopolysaccharide are EA5 and LA27, the DNA aptamer of the target peptidoglycan is Antibac2, and the DNA aptamer of the target flagellin is Aptamer 3; the sequence of the EA5 is shown as SEQ ID NO.1, the sequence of the LA27 is shown as SEQ ID NO.2, the sequence of the Antibac2 is shown as SEQ ID NO.3, and the sequence of the Aptamer 3 is shown as SEQ ID NO.4. The invention further discloses a kit for detecting the content of the EA5, the LA27, the Antibac2 and the Aptamer. According to the present invention, the six bacteria can be simultaneously detected, the detection limit is low, the operation process is simple, and the detection accuracy can achieve 97.6%.

This application relates to compositions and methods used to treat animals with at least one microbial protein, such as a flagellin protein. In embodiments, application relates to compositions and methods to treat animals with a fusion protein comprising at least one adjuvant protein, such as a flagellin protein. In embodiments, the composition further includes at least one adjuvantic protein fused with at least one antigen protein, and the fusion protein is expressed in diatoms.

The application belongs to the technical field of biology, and discloses a preparation method of a Salmonella typhimurium flagellin and Senecavirus antigen fusion protein. The application selects Escherichia coli Rosetta (DE3) as a host, fuses a Salmonella typhimurium flagellin gene and a Senecavirus antigen gene, optimizes codons, and then clones the fusion protein into a pET-28a (+) vector, so that the obtained fusion protein can keep the adjuvant activity of the flagellin, improve the solubility and expression level of VP2, and the yield can reach 40 mg / L, thereby greatly reducing the expression and purification process cost. The fusion protein provided by the application can activate the TLR5 path and activate mouse macrophages, and the production process is simple and low in cost, so that the application has important significance for the research and production of Senecavirus subunit vaccines.

The present invention relates to the manufacture and application of flagellin immunopotentiating derivatives with TLR5 activity using an eukaryotic cell expression system. The flagellin derivative according to the present invention has a high immunostimulatory effect and can be used in various vaccine and immunotherapy compositions.

The present invention relates to a FLT3L–flagellin hybrid adjuvant with enhanced antigen cross-presentation efficacy and a vaccine composition comprising same. The hybrid adjuvant of the present invention demonstrated significant therapeutic efficacy as an adjuvant for a therapeutic cancer vaccine in a preclinical mouse model of cervical cancer, resulting in complete tumor regression and sustained protection. In addition, the hybrid adjuvant of the present invention induced tumor-specific antigen CD8+ T cell responses and progenitor-exhausted CD8+ T cells (Tpex) due to an increase in cross-presentation by conventional type 1 dendritic cells (cDC1) in tumor-draining lymph nodes and the tumor microenvironment, and the combination of TCV having the hybrid adjuvant applied thereto and anti-PD-1 therapy significantly improves survival outcomes in anti-PD-1–resistant tumors, and thus can be advantageously applied in anticancer immunotherapy using therapeutic cancer vaccines.

The invention relates to a novel Toll-like receptor 5 agonist as well as a preparation method and application thereof, and provides a flagellin variant of which the amino acid sequence is shown as SEQ ID NO: 1. Or a sequence having at least 80%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or at least 99.5%, or at least 99.9% identity with the amino acid sequence as shown in SEQ ID NO: 1. The flagellin variant not only has low immunogenicity, but also can effectively prevent extremely severe bone marrow acute radiation injury, is good in stability, and shows a potential application value in radiation injury protection.

The present invention relates to the manufacture and application of flagellin immunopotentiating derivatives with TLR5 activity using an eukaryotic cell expression system. The flagellin derivative according to the present invention has a high immunostimulatory effect and can be used in various vaccine and immunotherapy compositions.

This invention discloses a sodium caseinate-based Pickering emulsion, its preparation method, and its application, belonging to the field of vaccine adjuvant technology. This invention is the first to propose using Salmonella Typhimurium flagellin and sodium caseinate as raw materials to formulate a Pickering emulsion. The prepared Pickering emulsion has the characteristics of small particle size, good biocompatibility, and high stability, and can induce a high immune response in the body. This invention is also the first to propose the application of the Pickering emulsion formulated using Salmonella Typhimurium flagellin and sodium caseinate as raw materials as a vaccine adjuvant. The Pickering emulsion prepared by this invention has a simple preparation process, requiring only mixing and homogenization, and can effectively load the model antigen OVA. This emulsion has good cellular safety and can promote the endocytosis of exogenous antigens by macrophages. The emulsion can induce the body to produce high levels of antibody titers, with antibody titers reaching more than 120,000 times.

The application provides a kind of chimeric flagellin and its application.The chimeric flagellin is formed by the chimeric of A type Seneca virus VP2 fragment and Escherichia coli Nissle 1917 flagellin FliC through Linker (GGGGS) 3, which realizes the soluble expression of chimeric flagellin in Escherichia coli system, and the yield can reach 200 mg / L at most. And through the detection of in vitro Caco2 and Raw264.7 cell models, the recombinant chimeric flagellin shows good TLR5 receptor activity, which can effectively activate TLR5 signal pathway.

The application belongs to the technical field of plant disease prevention and treatment, and discloses a flagellin and application of the flagellin in a plant immune elicitor. The flagellin is separated and extracted from Bacillus amyloliquefaciens Ba168, has good bacteriostatic activity, and has an immune induction effect on tobacco. The application realizes mass expression and purification of the flagellin by using genetic engineering technology. The flagellin can induce a plant immune response, can induce plant cell necrosis, plant active oxygen burst, and an increase of plant defense enzyme activity. The flagellin can induce plant resistance to PVX, and provides a new type of elicitor material for prevention and treatment of PVX.

The invention discloses a novel TCR-CAR plasmid for expressing flagellin, a CAR-T cell, a preparation method of the novel TCR-CAR plasmid and the CAR-T cell, and application of the novel TCR-CAR plasmid and the CAR-T cell in tumor resistance, and belongs to the technical field of CAR-T cells. By means of the innovative structural design, after CAR recognizes a target antigen, expression and secretion of flagellin can be started along with activation of T cells, the flagellin is released to a tumor site, after an activation signal disappears, release of the flagellin gradually fades away, and after the target antigen is recognized again, a new round of secretion and release is started. The technical problems that in the prior art, release of flagellin polypeptide cannot be accurately controlled, engineering immune cells release randomly, and then the anti-tumor effect cannot be achieved due to the fact that the engineering immune cells cannot effectively enter the tumor in the application of treating solid tumors can be effectively solved.

This invention relates to the field of biological protein application technology, and discloses the application of flagellin hypervariable region H as an intramolecular adjuvant in vaccine preparation. The amino acid sequence of flagellin hypervariable region H is shown in SEQ ID NO.3, and the nucleotide sequence of the gene encoding flagellin hypervariable region H is shown in SEQ ID NO.4. This invention also discloses an expression cassette, recombinant vector, recombinant cells, or recombinant bacteria containing the gene encoding flagellin hypervariable region H. This invention uses the aforementioned flagellin hypervariable region H as an intramolecular adjuvant in vaccine preparation. This invention connects flagellin hypervariable region H to an antigenic epitope to obtain a fusion protein. Compared with existing technologies, the solubility and activity of the fusion protein are improved. Simultaneously, this invention overcomes the expression form of inclusion bodies in existing E. coli expression systems, eliminating the need for subsequent refolding and assembly, thus simplifying the vaccine preparation process.

The application discloses a method for improving the anti-styrene stress ability of Gluconobacter oxydans, and belongs to the technical field of genetic engineering and microbial engineering. Firstly, the adaptability evolution of wild-type Gluconobacter oxydans to styrene is carried out by gradient addition of styrene in a culture medium, and finally, the evolved strain ST significantly improves the tolerance of Gluconobacter oxydans to styrene. Secondly, the knocking out of flagellin FlgE in Gluconobacter oxydans also improves the stress ability of Gluconobacter oxydans to styrene; the growth performance of the gene deletion Gluconobacter oxydans ST-ΔflgE prepared by the method of the application after 10h culture under 15g / L styrene is far better than that of the wild-type Gluconobacter oxydans.

The present invention relates to a ferritin nanocage-integrated vaccine comprising a flagellin immunoadjuvant, and a preparation method therefor. The present invention enables multivalent presentation of an antigen and a flagellin immunoadjuvant on the surface of a ferritin nanocage using a SpyTag–SpyCatcher system, thereby increasing efficiency of vaccine formulations, enhancing B cell maturation and memory formation, elevating T cell activation, and providing improved protective efficacy.

Provided herein are recombinant microorganisms that express a subject polypeptide. Microorganisms can comprise an expression construct comprising a flagellin promoter operatively linked with a heterologous nucleotide sequence encoding the subject polypeptide. The flagellin promoter sequence can comprise a genetic modification that reduces CsrA inhibition of translation. Microorganisms also can comprise a genetic modification that reduces FlgM inhibition of SigD initiation of transcription. The target polypeptide can be an aldehyde dehydrogenase. Such microorganisms are useful in the treatment of alcohol hangover.

The application discloses a primer for homologous recombination and scarless deletion detection of Vibrio parahaemolyticus flagellum protein loci, wherein the Vibrio parahaemolyticus flagellum protein loci comprises flaA, flaB, flaC, flaD, flaE and flaF genes, and the primer is specifically shown in Table 1; a scarless deletion construction method of the Vibrio parahaemolyticus flagellum protein loci is also disclosed, and application of the scarless deletion Vibrio parahaemolyticus flagellum protein loci constructed by the method in regulating motility, biofilm formation, adhesion capacity, virulence and immunogenicity of Vibrio parahaemolyticus is disclosed. The primer provided by the application realizes efficient scarless genetic operation of the Vibrio parahaemolyticus flagellum protein loci; the scarless deletion flagellum protein loci provided by the application significantly affect the motility, biofilm formation, adhesion capacity, virulence and immunogenicity of Vibrio parahaemolyticus, and have application prospects in Vibrio parahaemolyticus disease prevention and control.